Drug Trial Radar · NCT01903252
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Last checked: Nov 19, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
817
Actual
Start
Jul 2013
Primary completion
May 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Tillotts Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to) Asacol™(1). (1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.
Conditions
- Acute Ulcerative Colitis
Interventions
TP05Drug
3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
Asacol 400 mgDrug
3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Period 1: Clinical and Endoscopic RemissionTime frame: Week 8
- Period 2: Clinical Response, Open-Label Extended InductionTime frame: Week 16
- Period 3: Clinical RemissionTime frame: Week 38
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tillotts Pharma AG
Rheinfelden, Baslerstrasse 15, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.